With ADCs regularly cited as the hot topic of the antibody sector (and as perhaps focus moves away a little from traditional therapeutic mAbs) we're seeing more and more ADCs enter clinical development. Historically, only 3 ADCs have ever gained marketing approval – with the first, Pfizer's Gemtuzumab ozogamicin (Mylotarg) being withdrawn from market in June 2010. That leaves two ADCs currently on the market – Seattle Genetics' ADCETRIS and Genentech's Kadcyla.
However, recent years have seen a huge increase in the number of ADCs entering the clinic. 2009 and 2010 saw 8 ADCs enter the clinic, whereas at least 17 entered in 2011 and 2012. Currently there are 30 ADCs in various stages of clinical trials, across 24 indications Download this ebook to find out what they are, who is developing them and when we can expect to see the results.
Are you interested in learning more and engaging in discussion on mAbs, ADC's, bispecifics and antibody biosimilars? Do you want to hear the most recent updates on mAbs/ADC's at the clinical stage? Do you want to network with senior executives and opinion leaders from truly international antibody pioneers? Take a look at the European Antibody Congress 2013.